Schering-Plough Corp.'s

We said goodbye to Wyeth three weeks ago,
Pfizer (NYSE: PFE) took it from our sight.
Today it's Schering-Plough's heave-ho,
Merck (NYSE: MRK) closed the deal last night.

Washington -- Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S. authorities said.